Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Revenue Collapse • Rising Leverage • Liquidity Cushion ARWR faces sharply worsening profitability, cash flow, and leverage despite strong near-term liquidity, making its elevated valuation difficult to justify without a meaningful operating recovery.
Price Behavior
Key Price Behavior Insights: • Support rebound • Ceiling resistance • Neutral momentum Support Level: $82.39 Resistance Level: $88.60–$89.40 ARWR was range-bound last month, rebounding from $82.39 support but needing a sustained break above $89.40 to turn bullish.
Sentiment & News
Key News Insights: • Phase 3 success • EU market launch • Institutional buying Arrowhead's plozasiran Phase 3 success, reduced pancreatitis events, and early EU commercialization strengthen its growth outlook.
AI Summary
ARWR has shifted from a clinical-validation biotech to a commercial-execution story: plozasiran's compelling data and potential $3–$4B sHTG expansion offer major upside, but investors should require evidence of reimbursement-driven REDEMPLO revenue growth before overlooking persistent cash burn and rising leverage.
Description
Arrowhead Pharmaceuticals is a Pasadena-based biopharmaceutical company, founded in 1989, that develops RNA interference therapeutics for a range of liver, cardiovascular, pulmonary, rare genetic and oncology indications. Its clinical-stage pipeline includes candidates targeting liver-expressed proteins, cardiovascular lipid regulators, pulmonary targets and other disease-specific genes, and the company partners with Janssen and Takeda on several liver-directed programs. Arrowhead also participates in collaborations for subcutaneously administered RNAi candidates for chronic hepatitis B and other externally developed programs.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 4 | Feb 11 | ARWR | Arrowhead Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment. | Closed | -9.6% |
| Dec 2 | Dec 9 | ARWR | Arrowhead Pharmaceuticals, Inc. | Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout. | Closed | +18.8% |